Imagine anti-cancer therapies with fewer side effects and improved effectiveness. Starpharma is turning this dream into a reality, not just for cancer treatments but also for drugs to treat a range of diseases. It all stems from Starpharma's patented dendrimer nanoparticle drug delivery technology, which we refer to as ‘Dendrimer Enhanced Products’ or DEP® for short.
Starpharma's DEP® drug delivery platform aims to enhance the effectiveness of existing and novel therapies, including chemotherapeutic agents, radiotheranostics, and Antibody-Drug Conjugates (ADCs), while reducing drug-related toxicities through controlled and specified drug delivery.
DEP® has already been widely applied in oncology but can also be applied to other classes of drugs.
DEP® allows for more controlled and precise drug delivery, which provides therapeutic and commercial opportunities. DEP® allows for the creation of new intellectual property and extends the patent life of existing drugs. DEP® is versatile and can be applied to a wide range of therapeutic modalities, including small molecules, peptides, proteins, and nucleic acids such as mRNA. Because of this versatility, DEP® is often referred to as a platform drug delivery technology.